Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options

被引：3

作者：

Schmidt, Andrew ^{[1
]}

Azad, Arun ^{[2
]}

Goh, Jeffrey ^{[3
,4
]}

Harris, Carole ^{[5
,6
]}

Joshua, Anthony M. ^{[7
]}

Weickhardt, Andrew ^{[8
]}

Krieger, Laurence ^{[9
]}

机构：

[1] Liz Plummer Canc Ctr, Cairns, Qld, Australia

[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[3] Royal Brisbane & Womens Hosp, Butterfield St, Herston, Qld, Australia

[4] Univ Queensland, St Lucia, Qld, Australia

[5] St George Hosp, Kogarah, NSW, Australia

[6] Sutherland Clin Sch UNSW, Kogarah, NSW, Australia

[7] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia

[8] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia

[9] Royal North Shore Hosp, Northern Canc Inst, Reserve Rd, St Leonards, NSW, Australia

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷

关键词：

immuno-oncology; renal cell carcinoma; VEGF tyrosine kinase inhibitors; INTERFERON-ALPHA; PREEXISTING AUTOIMMUNE; OPEN-LABEL; EVEROLIMUS; SUNITINIB; EFFICACY; SURVIVAL; CANCER; NEPHRECTOMY; LENVATINIB;

D O I：

10.1111/ajco.13289

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.

引用

页码：3 / 10

页数：8

共 50 条

[41] Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting
de Velasco, Guillermo
Hamieh, Lana
Mickey, Suzanne
Choueiri, Toni K.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (12) : 538 - 545
[42] First-Line Therapy for untreated locally advanced, inoperable or metastatic Renal Cell Carcinoma
Rexer, Heidrun
von Amsberg, Gunhild
Doehn, Christian
AKTUELLE UROLOGIE, 2024, 55 (05)
[43] PISCES: A Horoscope for First-Line Targeted Therapy of Metastatic Renal Cell Carcinoma Reply
Escudier, Bernard
Porta, Camillo
Powles, Thomas
Eisen, Tim
Sternberg, Cora N.
Mehmud, Faisal
Cella, David
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33)
[44] New treatment options for metastatic renal cell carcinoma
Rodriguez-Vida, Alejo
Hutson, Thomas E.
Bellmunt, Joaquim
Strijbos, Michiel H.
ESMO OPEN, 2017, 2 (02)
[45] Proteinuria with first-line therapy of metastatic renal cell cancer
Land, Josiah D.
Chen, Adrienne H.
Atkinson, Bradley J.
Cauley, Diana H.
Tannir, Nizar M.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2016, 22 (02) : 235 - 241
[46] Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
Atkins, Michael B.
Tannir, Nizar M.
CANCER TREATMENT REVIEWS, 2018, 70 : 127 - 137
[47] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
Remak, Edit
Charbonneau, Claudie
Negrier, Sylvie
Kim, Sindy T.
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
[48] TOLERABILITY OF TARGETED AGENTS IN FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC)
Su, Y.
Shi, N.
Landsman-Blumberg, P.
Poehlein, C.
Waxman, I.
ANNALS OF ONCOLOGY, 2012, 23 : 267 - 268
[49] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
Emilio, Mucino-Ortega
Joaquin Federico, Mould-Quevedo
GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
[50] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
Prieto, V. A.
Reyes, J. M.
Lopez-Cabra, C.
Diaz, J. A.
Urrego-Novoa, J. R.
VALUE IN HEALTH, 2016, 19 (03) : A149 - A149

← 1 2 3 4 5 →